Neoplastic Meningitis
Neoplastic meningitis responded modestly to intracerebrospinal fluid etoposide
Published in Cancer Weekly, July 18th, 2006
According to a study from the United States, "The purpose of the current study was to determine the toxicity and response of a fixed dose CSF etoposide in the treatment of patients with newly diagnosed NM. NM reportedly occurs in 1% to 5% of patients with known cancer."
"Currently available treatment options are limited and provide only modest benefit. Twenty-seven patients (median age, 55 yrs) with clinically and cytologically documented NM received intra-CSF etoposide. Tumor histologies included lung (8 patients), breast (5 patients), primary brain tumor (4...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-07-18)
More Articles from Cancer Weekly
- Head & Neck Cancer
Head and neck cancer-related tumor hypoxia detected by positron emission tomography - Oral Cancer
Oral cancer metastases detected by F-18-FDG PET/CT - Oropharyngeal Cancer
Oropharyngeal carcinoma patient quality of life influenced by gender - Prostate Cancer
Prostate cancer responded to synergistic effects of radiation and beta-lapachone - Acute Myeloid Leukemia
Acute myeloid leukemia prognosticated by size of FLT3 internal tandem duplication - Adrenocortical Cancer
Adrenocortical carcinoma outcome predicted by tumor grade, tumor stage, and surgical resection - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
